New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study, could lead to a “difficult path ahead” for Keros, according to Guggenheim analysts.